ReviewFrontiers in pharmacology2026
Drug repurposing of sophoridine for sepsis-induced organ injury: from in-depth analysis of a single agent to a multi-target therapeutic paradigm.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-induced immune dysregulation and multiple organ dysfunction present formidable clinical challenges that conventional single-target therapies fail to address. This review evaluates the potential of the natural quinolizidine alkaloid sophoridine for drug repurposing in sepsis. Pharmacological evidence demonstrates that sophoridine exerts multi-target synergistic effects by modulating the nuclear factor-κB (NF-κB) signaling pathway, the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, and programmed cell death pathways. To overcome translational hurdles such as temporal progression and microenvironmental heterogeneity, we propose a precision therapeutic framework. This strategy integrates biomarker-driven dynamic dosing, nanotechnology-enabled targeted delivery, and multi-omics-guided systems pharmacology. Ultimately, this paradigm aims to provide a rigorous theoretical basis for developing personalized, spatiotemporally controlled interventions for sepsis-associated organ injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.